Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues

Bioorg Med Chem Lett. 2015;25(10):2112-6. doi: 10.1016/j.bmcl.2015.03.077. Epub 2015 Mar 31.

Abstract

The continuous development of drug resistance by Plasmodium falciparum, the agent responsible for the most severe forms of malaria, creates the need for the development of novel drugs to fight this disease. Fosmidomycin is an effective antimalarial and potent antibiotic, known to act by inhibiting the enzyme 1-deoxy-d-xylulose-5-phosphate reductoisomerase (DXR), essential for the synthesis of isoprenoids in eubacteria and plasmodia, but not in humans. In this study, novel constrained cyclic prodrug analogues of fosmidomycin were synthesized. One, in which the hydroxamate function is incorporated into a six-membered ring, was found have higher antimalarial activity than fosmidomycin against the chloroquine and mefloquine resistant P. falciparum Dd2 strain. In addition, it showed very low cytotoxicity against cultured human cells.

Keywords: Antimalarial; Fosmidomycin; Hydroxamates; Phospha-Michael; Phosphonates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / chemical synthesis*
  • Antimalarials / pharmacology*
  • Drug Evaluation, Preclinical
  • Fosfomycin / analogs & derivatives*
  • Fosfomycin / chemical synthesis
  • Fosfomycin / pharmacology
  • Humans
  • Prodrugs / chemical synthesis*
  • Prodrugs / pharmacology*

Substances

  • Antimalarials
  • Prodrugs
  • Fosfomycin
  • fosmidomycin